

YIFAN INTERNATIONAL PHARMACEUTICAL CO., LIMITED
(Company Registration No.: 2141494)
(Incorporated in the Hong Kong Special Administrative Region
of the People's Republic of China)

**COMPLETION OF COMPULSORY ACQUISITION
UNDER SECTION 215(1) OF THE COMPANIES ACT, CHAPTER 50 OF SINGAPORE,
AND DELISTING**

1. Introduction

The sole director (the “**Board**”) of Yifan International Pharmaceutical Co., Limited (the “**Offeror**”) refers to:

- (i) the voluntary conditional general offer (the “**Offer**”) by SAC Capital Private Limited (“**SAC Capital**”), for and on behalf of the Offeror, for all the issued and paid-up ordinary shares in the capital of SciGen Ltd (the “**Company**”) (excluding treasury shares) (the “**Shares**¹”), other than those Shares already owned, controlled, or agreed to be acquired by the Offeror as at 9 July 2018, but including Shares owned, controlled, or agreed to be acquired by parties acting or deemed to be acting in concert with the Offeror in accordance with Rule 15 of the Singapore Code on Takeovers and Mergers, which was declared unconditional in all respects on 11 July 2018 and which closed at 5.00 p.m. (Singapore time) / 7.00 p.m. (Sydney time) on 7 August 2018; and
- (ii) the announcement dated 21 August 2018 issued by SAC Capital for and on behalf of the Offeror in relation to the exercise of its right of compulsory acquisition (the “**Compulsory Acquisition**”) under Section 215(1) of the Companies Act, Chapter 50 of Singapore (“**Companies Act**”) to compulsorily acquire all the Shares held by the shareholders who have not accepted the Offer (the “**Dissenting Shareholders**”) at the offer price of US\$0.0507 in cash for each Share.

2. Completion of Compulsory Acquisition under Section 215(1) of the Companies Act

The Offeror wishes to announce that the Compulsory Acquisition was completed on 27 August 2018 (the “**Announcement**”). As at date of this Announcement, the transfer of all the Shares of the Dissenting Shareholders to the Offeror has been effected and payment for such Shares has been despatched. Accordingly, the Company has become a wholly-owned subsidiary of the Offeror.

3. Delisting

In view of the completion of the Compulsory Acquisition, the Australian Securities Exchange (“**ASX**”) has suspended the Company's CDIs from trading on 22 August 2018, and will

¹ Shares include securities which may be transmuted into Shares, such as CHESS Depository Interests in the Company (“**CDIs**”) in respect of which the underlying and corresponding security is one Share for each CDI, and such Shares being held by CHESS Depository Nominees Pty Limited on behalf of holders of CDIs. For the purposes of the Offer, references to Shareholders shall also include the holders of CDIs in the Company.

remove the Company from the official list of the ASX at the close of trading on 28 August 2018, as per the Company's announcements released on the ASX's website on 6 August 2018 and 21 August 2018.

4. Responsibility Statement

The sole director of the Offeror has taken all reasonable care to ensure that the facts stated and all opinions expressed in this Announcement are fair and accurate and that there are no other material facts not contained in this Announcement, the omission of which would make any statement in this Announcement misleading, and that he accepts responsibility accordingly.

Where any information in this Announcement has been extracted or reproduced from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the sole director of the Offeror has been to ensure through reasonable enquiries that such information has been accurately and correctly extracted from such sources and/or, as the case may be, reflected or reproduced in this Announcement in its proper form and context.

BY ORDER OF THE BOARD

For and on behalf of Yifan International Pharmaceutical Co., Limited

Cheng Xianfeng

27 August 2018